3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Polycythemia Vera
3
Thrombocythemia, Essential
2
Philadelphia Chromosome
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Brain Neoplasms
2
Skin Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Leukemia
1
Glioma
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Blast Crisis
1
Interventions
Cyclophosphamide
192
Methotrexate
106
Cytarabine
86
fludarabine phosphate
80
Busulfan
71
Tacrolimus
70
Peripheral Blood Stem Cell Transplantation
69
Mycophenolic Acid
69
Whole-Body Irradiation
68
Vincristine
67
fludarabine
61
Filgrastim
61
Etoposide
59
Dexamethasone
54
Melphalan
52
Radiotherapy
47
Rituximab
46
Cyclosporine
46
Doxorubicin
38
Antilymphocyte Serum
37
Thiotepa
35
Granulocyte Colony-Stimulating Factor
35
Prednisone
34
Mercaptopurine
34
blinatumomab
33
pegaspargase
27
Methylprednisolone
27
Daunorubicin
26
Clofarabine
26
Asparaginase
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
peginterferon alfa-2a
×
Clear all
NCT00763763
2011-10-05
AFR07
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
55 enrolled